AU6919300A - Methods for in vivo gene delivery to sites of cartilage damage - Google Patents

Methods for in vivo gene delivery to sites of cartilage damage

Info

Publication number
AU6919300A
AU6919300A AU69193/00A AU6919300A AU6919300A AU 6919300 A AU6919300 A AU 6919300A AU 69193/00 A AU69193/00 A AU 69193/00A AU 6919300 A AU6919300 A AU 6919300A AU 6919300 A AU6919300 A AU 6919300A
Authority
AU
Australia
Prior art keywords
sites
methods
gene delivery
vivo gene
cartilage damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69193/00A
Inventor
Christopher H Evans
Steven C. Ghivizzani
Paul D Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU6919300A publication Critical patent/AU6919300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
AU69193/00A 1999-08-20 2000-08-18 Methods for in vivo gene delivery to sites of cartilage damage Abandoned AU6919300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15011899P 1999-08-20 1999-08-20
US60/150118 1999-08-20
PCT/US2000/022801 WO2001013960A1 (en) 1999-08-20 2000-08-18 Methods for in vivo gene delivery to sites of cartilage damage

Publications (1)

Publication Number Publication Date
AU6919300A true AU6919300A (en) 2001-03-19

Family

ID=22533193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69193/00A Abandoned AU6919300A (en) 1999-08-20 2000-08-18 Methods for in vivo gene delivery to sites of cartilage damage

Country Status (2)

Country Link
AU (1) AU6919300A (en)
WO (1) WO2001013960A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259174A1 (en) * 2000-04-28 2001-11-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US20030175257A1 (en) * 2002-03-12 2003-09-18 Song Sun Uk Cartilage regeneration using chondrocyte and TGF-beta
US20050118655A1 (en) 2003-11-17 2005-06-02 University Of Iowa Research Foundation Use of parasitic biological agents for diseases prevention and control
AU2004293474B2 (en) * 2003-11-24 2010-12-23 Canji, Inc. Reduction of dermal scarring
AU2014317861B2 (en) * 2013-09-09 2019-11-28 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011359A1 (en) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education A truncated interleukin-1 receptor gene for the treatment of arthritis
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
AU1513495A (en) * 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration

Also Published As

Publication number Publication date
WO2001013960A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
AU1618201A (en) Methods for inducing chondrogenesis and producing de novo cartilage in vitro
AU1100201A (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
AU1954001A (en) Methods for high level expression of genes in primates
AU2543795A (en) Methods of in vivo gene delivery
AU1939801A (en) In situ bioreactors and methods of use thereof
AU2001294890A1 (en) Pei: dna vector formulations for in vitro and in vivo gene delivery
AU4460900A (en) Carrier patch for the delivery of agents to the skin
AU5143300A (en) Methods for delivering in vivo uniform dispersed embolic compositions of high viscosity
AU6379700A (en) Method of promoting bone growth with hyaluronic acid and growth factors
AU4996300A (en) Method of electroporation-enhanced delivery of active agents
EP1594883A4 (en) Covalent modification of rna for in vitro and in vivo delivery
HK1039571A1 (en) Compositions and methods for mucosal delivery
AU6324300A (en) Releasable connector
AU1261501A (en) Compositions and methods for intranasal delivery of active agents to the brain
HK1048593A1 (en) Techniques and compositions for treating cardiovascular disease by i in vivo /i gene delivery
AU2191901A (en) Improvements relating to information delivery
AU3499500A (en) Combinations and methods for promoting (in vivo) liver cell proliferation and enhancing (in vivo) liver-directed gene transduction
AU6919300A (en) Methods for in vivo gene delivery to sites of cartilage damage
AU2001238485A1 (en) Methods and compositions for gene delivery
AU1683200A (en) Method for improving gelling properties of protein
AU2899800A (en) Compounds and methods for stimulating gene expression and cellular differentiation
AU2416800A (en) Method and system for low volume buyers to aggregate purchasing power
AU6094200A (en) Nor gene compositions and methods for use thereof
AU7954500A (en) Method of in vitro culture of lymphocytes and gene therapy compositions
EP1173192A4 (en) Methods and compositions for targeted drug delivery

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase